Nijssen, E. C.
Nelemans, P. J.
Rennenberg, R. J.
van Ommen, G. V.
Wildberger, J. E.
Article History
Received: 28 February 2022
Revised: 29 April 2022
Accepted: 8 June 2022
First Online: 28 June 2022
Declarations
:
: The scientific guarantor of this publication is Prof. J.E. Wildberger.
: The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article. J.E. Wildberger reports grants and fees unrelated to contents of this article: institutional grants via Clinical Trial Center Maastricht from Agfa, Bard, Bayer, Cook, GE, Philips, Optimed, Radiomics, and Siemens and speaker’s bureau via Maastricht UMC+ from Bayer and Siemens.
: One of the authors has significant statistical expertise.No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all patients participating in the AMACING trial.
: Institutional Review Board approval was obtained.
: Results of the AMACING trial up to 1 month and year have been previously reported in: Nijssen et al, <i>Lancet</i> 2017; 389: 1312–22 and Nijssen et al. <i>EClinicalMedicine by the Lancet</i> 2018;4–5:109–116. Effects of guideline updates on patient and hospital burden have been previously reported in Nijsen et al. <i>Eur Radiol</i> 2020; 30: 4005-4013.
: • The AMACING trial is a prospective randomised controlled trial performed at one institution.